Over the past two decades there has been a worldwide increase in the prevalence of obesity. In the United States 60% of the population is either overweight or obese. As a result, rates of obesity related co-morbities, particularly type II diabetes are increasing. Furthermore due to rising rates of obesity in the young, type II diabetes is now seen even in adolescence patients. This creates a demand for more and better therapeutic agents, potentially focused on novel pathways. Recently, FGF21 has emerged as a hepatic regulatory factor that acts on multiple remote targets including white adipose tissue but importantly also mediates effects on the liver itself in an autocrine fashion. We have found that FGF21 is an essential mediator of fatty acid oxidation in the liver, during ketosis, both in animals consuming a very low carbohydrate ketogenic diet and during fasting;others have reported improvements in glucose homeostasis in obese animals treated with FGF21 infusions. However, much remains to be elucidated regarding the biology of FGF21.
The aims of this grant are to investigate the physiology and action of FGF21 both to improve our understanding of this hormone and to better assess the therapeutic potential of FGF21 as a future treatment of obesity and diabetes. To achieve this goal, we propose several lines of experimentation.
In specific aim 1 we will evaluate the role FGF21 to regulate both glucose homeostasis and fatty acid oxidation during fasting. In addition we will generate two mouse models to determine the role of FGF21 in different tissues. In the second aim we will expand our work on obesity as FGF21 resistant state by exploring potential mechanisms that contribute to resistance which we have documented in both fat and liver. In this aim we will also evaluate the role of dual specificity phosphatases (DUSPs) in modulating FGF21 action. In the third specific aim we will focus on our recent finding that FGF21 acts on both brown adipose tissue and white adipose tissue in a manner suggesting a role to promote energy expenditure. In the fourth aim we will examine central effects of FGF21 and map target areas of the CNS that mediate these effects.

Public Health Relevance

Obesity and type II diabetes are major problems threatening the health of the US population and new therapies are needed. FGF21 has emerged as a hormone made predominantly in the liver that acts to improve metabolism, especially in the obese state. This grant focuses on the metabolic actions of FGF21 and the molecules mediating these actions as such understanding is important for both developing treatments and preventing obesity and diabetes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK028082-30
Application #
8316105
Study Section
Special Emphasis Panel (ZRG1-EMNR-N (02))
Program Officer
Hyde, James F
Project Start
1981-03-01
Project End
2015-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
30
Fiscal Year
2012
Total Cost
$561,317
Indirect Cost
$238,721
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Singhal, Garima; Douris, Nicholas; Fish, Alan J et al. (2016) Fibroblast growth factor 21 has no direct role in regulating fertility in female mice. Mol Metab 5:690-8
Singhal, Garima; Fisher, Ffolliott Martin; Chee, Melissa J et al. (2016) Fibroblast Growth Factor 21 (FGF21) Protects against High Fat Diet Induced Inflammation and Islet Hyperplasia in Pancreas. PLoS One 11:e0148252
Domouzoglou, Eleni M; Naka, Katerina K; Vlahos, Antonios P et al. (2015) Fibroblast growth factors in cardiovascular disease: The emerging role of FGF21. Am J Physiol Heart Circ Physiol 309:H1029-38
Douris, Nicholas; Stevanovic, Darko M; Fisher, Ffolliott M et al. (2015) Central Fibroblast Growth Factor 21 Browns White Fat via Sympathetic Action in Male Mice. Endocrinology 156:2470-81
Douris, Nicholas; Melman, Tamar; Pecherer, Jordan M et al. (2015) Adaptive changes in amino acid metabolism permit normal longevity in mice consuming a low-carbohydrate ketogenic diet. Biochim Biophys Acta 1852:2056-65
Fisher, Ffolliott Martin; Maratos-Flier, Eleftheria (2015) Understanding the Physiology of FGF21. Annu Rev Physiol :
Hong, Shangyu; Moreno-Navarrete, Jose M; Wei, Xiaojing et al. (2015) Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization. Nat Med 21:887-94
Dushay, Jody R; Toschi, Elena; Mitten, Emilie K et al. (2015) Fructose ingestion acutely stimulates circulating FGF21 levels in humans. Mol Metab 4:51-7
Domouzoglou, Eleni M; Fisher, Ffolliott Martin; Astapova, Inna et al. (2014) Fibroblast growth factor 21 and thyroid hormone show mutual regulatory dependency but have independent actions in vivo. Endocrinology 155:2031-40
Fisher, Ffolliott M; Chui, Patricia C; Nasser, Imad A et al. (2014) Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. Gastroenterology 147:1073-83.e6

Showing the most recent 10 out of 49 publications